Xenon Pharmaceuticals (XENE) Shares Outstanding (Weighted Average) (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Shares Outstanding (Weighted Average) data on file, last reported at $87.3 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $87.3 million, up 11.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $87.3 million (up 11.0% YoY), and the FY2025 annual result was $2.2 million, down 97.21% from the prior year.
• Shares Outstanding (Weighted Average) climbed to $87.3 million in Q1 2026 per XENE's latest filing, from $2.2 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $87.3 million in Q1 2026 and troughed at $1.8 million in Q3 2023.
• A 5-year average of $47.5 million and a median of $58.8 million in 2022 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Weighted Average) slumped 96.89% in 2023, then jumped 4160.93% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $3.1 million in 2022, then jumped by 2055.02% to $66.9 million in 2023, then sank by 96.75% to $2.2 million in 2024, then changed by 0.0% to $2.2 million in 2025, then jumped by 3919.44% to $87.3 million in 2026.
• Business Quant data shows XENE's Shares Outstanding (Weighted Average) at $87.3 million in Q1 2026, $2.2 million in Q4 2025, and $79.0 million in Q3 2025.